, the x − y plane represents the genotypes and the height of the landscape above this plane represents fitness. Two evolutionary trajectories, both starting from a wild-type genotype (yellow circle), are shown. These trajectories diverge at an evolutionary saddle point (blue triangle) and terminate at distinct local optima of fitness (purple pentagon, green star). As the saddle point exists, evolutionary trajectories need not be repeatable. B) Schematic landscapes for a potential follow-up drug are shown, the collateral response can be (i) always cross-resistant, (ii) always collaterally sensitive or (iii) dependent on the evolutionary trajectory that occurs stochastically under the first drug. C) A potential evolutionary branching point in the TEM gene of E. coli identified in the fitness landscape for cefotaxime derived by Mira et al. [21] .
known genotypes to form a fitness landscape. However, to derive fitness landscapes through this 91 method, the number of strains that must be engineered grows exponentially with the number of 92 mutations of interest. Thus only small, combinatorially complete, portions of the true fitness 93 landscape can be measured, for example consisting of 2-5 alleles [8, 25, 36] . Nevertheless, these 94 restricted fitness landscapes can provide valuable insight into the evolution of drug resistance. Figure S1 ), using the average growth rate (over 12
replicates) as a proxy of fitness. Of these 15 landscapes, 14 were identified as having multiple 99 local optima of fitness, indicating the potential for the divergence of evolutionary trajectories.
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We utilised these landscapes, coupled with a previously published mathematical model [23] (see A schematic of the model used to derive collateral response. Sequential mutations are simulated to fix in the population until a local optimum genotype arises. The fitness of this resultant genotype is compared to the fitness of the wild-type genotype for each of the panel of antibiotics.
B) The landscape for ampicillin derived by Mira et al. [21] represented as a graph of genotypes. Arrows indicate fitness conferring mutations between genotypes represented as nodes. Cyan nodes indicate genotypes from which evolution can stochastically diverge, grey nodes indicate genotypes from which there is only a single fitness conferring mutation. Squares indicate local optima of fitness with colour indicating the ordering of fitness amongst these optima (darker red indicates higher fitness). Two divergent evolutionary trajectories, in the sense of the model shown schemaically in A, are highlighted by coloured arrows. C) The best, worst, most likely and mean tables of collateral response derived through stochastic simulation of the experimental protocol. Columns indicate the drug landscape under which the simulation was performed and rows indicate the follow-up drug under which the fold-change from wild-type susceptibility is calculated. Bar charts indicate, for each labelled first drug, the number of follow-up drugs exhibiting collateral sensitivity (blue) or cross resistance (red) in each case. • Random pairs induce collateral resistance with probability p=0.58
• Pairs with reported collateral sensitivity induce collateral resistance with probability p=0.52
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This fitness function represents a genotype-phenotype map in the simplest sense -assigning to each 68 genotype a single real-valued fitness. Gillespie [1983, 1984] showed that if the mutation rate u and 69 population size M of a population satisfy Mu log M << 1, and if we assume that each mutation 70 is either beneficial or deleterious, then each beneficial mutation in the population will either reach 71 fixation or become extinct before a new mutation occurs. Further, selection will be sufficiently
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This fitness function represents a genotype-phenotype map in the simplest sense -assigning to each 68 genotype a single real-valued fitness. Gillespie [1983, 1984] showed that if the mutation rate u and 69 population size M of a population satisfy Mu log M << 1, and if we assume that each mutation 70 is either beneficial or deleterious, then each beneficial mutation in the population will either reach 71 fixation or become extinct before a new mutation occurs. Further, selection will be sufficiently 72 strong that any deleterious mutation will become extinct with high probability and hence we may we do not allow deleterious mutations to fix in the population.
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Using this Markov Chain we can explore the possible evolutionary trajectories of a p fig. 3) . We attributed the differithin a given drug(s) group to be the result hanges acquired by the isolates through cid-amikacin isolates (antagonistic interactary data S1, Supplementary Material online) increase in resistance improvement followed s adapted to doxycycline-ciprofloxacin (synon, supplementary data S1, Supplementary . Isolates evolved to ciprofloxacin-ampicillin tion, supplementary data S1, Supplementary had the least resistance improvement, an the WT MIC value. These results contrast ports based on sub-MIC adaptations, which Exposure 3 re of WT S. aureus was used to inoculate microtiter Three replicate populations were recreated for each and then used to inoculate the next concentration tion. (Fig. 1) . New clones arising after the establishment of the early tumor likely have little effect on the fitness of the presence of abnormally motile cells early in the tumor's development. Tumors with these mutation patterns, which are described as "born to be bad, " have increased risk of both invasive growth and metastatic spread.
The genotype-phenotype map
An ecological view of cancer has emerged in recent years, one that explicitly considers cancer as much more than a collection of mutated cells and embraces a more dynamic dialog between tumor and host [6] [7] [8] . Critical to this view are interactions between tumor cells, between tumor and stroma, and between the tumor and its environment. Evolution and ecology are intimately entwined through mutation and selection, and both have a central role in tumor progression. However, we must understand not only the identity of the mutations that drive evolution but also the mechanisms through which these mutations manifest themselves in phenotypic change, that is, the genotype-phenotype map ( Fig. 1) . This mapping is not one to one but many to many and is fundamentally the junction at which both genes and the environment meet to produce phenotypes. Recent work has shown that the complexity inherent within the genotype-phenotype map is responsible for the difficulty in predicting evolution 9
; many genotypes produce identical phenotypes, and many phenotypes can emerge from a single genotype 10 . This environment may exist before the mutation, or it may be created by the mutation through feedback. In the Big Bang model of clonal growth (right), the environment has a minimal role, and fitness differences are less important than mutation timing. Early driver mutations establish a tumor that is difficult to replace through fitness advantages alone. This figure was created during a brainstorming session with Chandler Gatenbee, Jill Gallaher and Daniel Nichol, and the final version was drawn by Chandler Gatenbee. not well founded although drugs within a class, for example the cephalosporins, show more correlation that those between groups. An ideal pair of drugs for use in an alternating fashion would have a high negative correlation such that the evolution of resistance under one drug would induce sensitivity to a second. Unfortunately, no such drug pair exists and we must employ more sophisticated methods to identify viable sequential drug strategies. We next performed an in silico derivation of tables of collateral response, or collateral sensitivity matrices (CSMs), by simulation of evolution with the model described by Equation 3.4. These simulations mirror the experimental techniques used to derive empirical collateral response, for example those used by Imammovic and Sommer [131] to determine drug cycling protocols. Evolutionary trajectories in each drug fitness landscape, f x , were stochastically simulated from the wild-type starting genotype (g 0 = 0000) by sampling the associated Markov chain defined by P x (Equation 3.4). The simulation was terminated when the evolutionary trajectory encountered a local optimum genotype, g * x . The fitness of this final genotype in the second drug landscape, f y , was then recorded and collateral response was calculated as
These collateral response measures we collated to form a table.
We can count the total number of CSMs that can be generated through this simulation. There exist 3 landscapes with only one peak accessible from the genotype g 0 = 0000, 6 in which two peaks are accessible, 4 in which three peaks are accessible and 2 in which four peaks are accessible. Assuming that for each landscape, f x , evolution is simulated from g 0 a single time to determine g * x and then the collateral sensitivity of g * x in each of the other landscapes, f y is recorded. Then there exist
Drug:
l 
that can be generated through this simulation. accessible from the genotype g 0 = 0000, 6 in hree peaks are accessible and 2 in which four landscape, f x , evolution is simulated from g 0 ollateral sensitivity of g * x in each of the other Figure 3 .4. The remainder of the scatter plots are presented in Appendix 1.
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We exhaustively explored all evolutionary trajectories in the 15 small antibiotic landscapes to identify potentially divergent collateral response. We found a total of 82944 unique CSMs. The most common CSM occurs with probability 0.0023. (>5kb) deletions, and replicate-specific sites for insertion of IS1D ( Table 2) . None of these
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were deemed likely to impact cefotaxime resistance as they do not occur in genes known to be 175 associated with drug resistance. As such, we conclude that mutations in SHV-1 are the primary 176 drivers of cefotaxime resistance. For example, for replicate X12, which exhibits the highest 177 endpoint MIC, no additional mutations were detected. In contrast, X1, X5, X8, X9, and X11
178
all had genomic mutations, lacked SHV-1 variants, and had the lowest final cefotaxime MIC.
179
Thus, the SHV-1 mutations appear to be the primary factor determining primary resistance. We 
186
We note that X7 exhibits an increase in resistance to cefotaxime without any associated 187 genomic alterations. Similarly X1, X5, X9 and X12 exhibit mutations, but none that are known 188 to be associated with antibiotic resistance. Thus, we can infer that physiological adaptation or 189 epigenetic adaptation is also driving resistance to cefotaxime.
191
Collateral Sensitivity Likelihoods
192
Our experimental results demonstrate that the evolution of antibiotic resistance is non- Table 2 . Mutations identified through whole genome sequencing. The single nucleotide variants (SNVs) both within SHV and elsewhere, insertions and deletions identified through whole genome sequencing of the replicates X1-X12 following passage 10 are list.
the in silico evolution model. We note that whilst there exist 28 drug pairs exhibiting guaranteed 
Where no such fitter neighbour exists, the process is terminated. The value of r determines the 287 extent to which the fitness benefit of a mutation biases the likelihood that it becomes the next 288 population genotype. We take r = 0, corresponding to fixation of the first arising resistance as the fold difference between g 0 and g * in a second fitness landscape.
295
The code used to implement the model, produce the figures and analyse the experimental 296 data is available upon request and will be made publicly available upon publication.
297
Experimental Adaptation to Cefotaxime
298
All 60 evolutionary replicates were derived from E. coli DH10B carrying phagemid pBC SK(-)
299
expressing the β-lactamase gene SHV-1 [28] . All evolutionary experiments were performed using 300
Mueller-Hinton agar.
301
Using a spiral plater, cefotaxime solution was applied to Mueller Hinton (MH) agar plates in a 302 continuously decreasing volume equivalent to a thousand-fold dilution. E. coli DH10B pBCSK(-) 303 bla SHV-1 colonies were suspended to a concentration of 7log10 CFU/ml in MH broth. Antibiotic 304 plates were then swabbed along the antibiotic gradient with the bacterial suspension. Plates were incubated overnight at 37°C. The most resistant colonies, as measured by the distance of growth along the gradient, were resuspended and used to swab a freshly prepared antibiotic 307 plate. The process was repeated for a total of 10 passages. The entire experiment was completed 308 60 times using the same parental strain to generate the cefotaxime resistance replicates X1-X60.
309

Determination of Minimum Inhibitory Concentration
310
The minimum inhibitory concentration of each antibiotic was determined for both the parent 
313
Where the MIC exceeded the maximum concentration considered, 4096 µg/ml, the precise value
314
was not determined and a lower bound MIC of ≥8192µg/ml was taken.
315
The MIC was determined from the replicates by maximum likelihood estimation using a statistical model outlined by Weinreich et al. [35] . Briefly, we assume that the j th log 2 transformed MIC measurement for the i th evolutionary replicate, under the drug d, denoted x d i,j , is determined as replicates and drugs. Note the assumption that we never erroneously take a measurement that 319 differs from the true MIC by greater than a factor of two. This is justified by noting that in no 320 instance do the maximum and minimum MICs measured in our analysis differ by greater than 321 Table X) . , except in the case that two of these values are precisely 4× the other, in which case the mle is the mid-point between the maximum and minimum. Letting r denote the number of replicate/drug combinations in which all three measurements equal the mle, s denote the number in which 2/3 measurements equal the mle, t the number in which 1/3 equal the mle and u the number in which 0/3 equal the mle. Then the mle for p is given by p = s + 2t + 3u 3(r + s + t + u) .
4× (Supplementary
This identity can be verified by first principles (by taking the derivative of the likelihood function)
323
but is also quite intuitive -it is simply the proportion of measurements that differ from the 324 inferred mle for the MIC. In our experiment, r = 338, s = 196, t = 11 and u = 4, which yields an 325 mle for the measurement error rate of p = 0.14.
326
The full data set, along with the inferred MIC values, are presented in Supplementary Table   327 1.
328
Collateral Sensitivity Analysis and Significance Testing
329
To determined collateral sensitivity (or cross resistance) we determined which evolutionary 
Otherwise, the set CR = 0.
336
Targeted Sequencing of SHV
337
Plasmid DNA was isolated using the Wizard Plus Minipreps DNA purification systems (Promega).
338
Sequencing of the SHV gene was performed using M13 primers (MCLab, Harbor Way, CA). Affairs.
